date: Wednesday June 16, 2021
time: 15.00 CET (Europe time)
overview:
Manufacturing dietary supplements poses many challenges related to tablet quality. Such challenges include cracking, chipping, breakage, crumbling, compressibility. The optimization of formulations can significantly improve performance and cost efficiency while reducing production issues. A key functional ingredient in any tablet formulation is a properly functioning binder. A product issue may indicate that a particular nutraceutical product was formulated with the most effective binder.
Ashland’s nutraceutical portfolio is uniquely suited to overcome the formulation challenges of dietary supplements, including working with ingredients that are difficult to compress, trying to reduce tablet size, and creating supplements that meet an organic standard. This webinar will review ways to overcome these challenges.
key objectives:
our speakers:
Daniel Sieber
pharmaceutical scientist
Daniel is a pharmaceutical scientist in the technical service and R&D team in EMEA at Ashland Life Science Division based in Düsseldorf, Germany, with a strong focus on technical support for Ashland’s products, especially in the fields of solid oral dosage forms in pharmaceutical and nutraceutical applications.
Daniel Sieber co-authored numerous scientific articles, book chapters and posters. He studied pharmacy at the Heinrich-Heine-University of Düsseldorf and received his degree as a pharmacist in 2012. After experiencing the work for a contract manufacturer in the pharmaceutical industry he started his Ph.D. studies at the university of Düsseldorf and joined Ashland’s technical service team in 2016.
Kapish Karan
technical leader - nutrition & nutraceutical NA
Kapish Karan, M.S. is a Senior Team Leader, Pharmaceutical and Nutraceutical R&D and Global Film-Coating Platform Leader, at Ashland. He has over 7 years of experience with film-coating applications, the design of immediate- and modified-release coating products, unit operations associated with the preparation of oral solid dosage forms, and oral drug delivery; his recent interests have expanded into continuous processing as it relates to the manufacture of oral solid dosage forms.